Race to save lives during sudden, deadly lung crises
NCT ID NCT07299695
Summary
This study is testing if adding intravenous immunoglobulin (IVIG) to standard hospital care helps patients with idiopathic pulmonary fibrosis (IPF) who are hospitalized for a sudden, severe worsening of their lung disease. The main goal is to see if IVIG can reduce deaths in the hospital or the need for a breathing tube. It will involve about 196 adults who are hospitalized with this type of severe flare-up.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Respiratory Medicine, University Hospital of Patras
RECRUITINGPátrai, 26504, Greece
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.